| Pulmonary arterial hypertension
Adcirca vs Tracleer
Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.Deep comparison between: Adcirca vs Tracleer with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTracleer has a higher rate of injection site reactions vs Adcirca based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tracleer but not Adcirca, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Adcirca
Tracleer
At A Glance
Oral
Daily
PDE5 inhibitor
Oral
Twice daily
Endothelin receptor antagonist
Indications
- Pulmonary arterial hypertension
- Pulmonary arterial hypertension
Dosing
Pulmonary arterial hypertension 40 mg (two 20 mg tablets) once daily with or without food; dividing the dose over the course of the day is not recommended. Start at 20 mg once daily for mild or moderate renal impairment (creatinine clearance 31 to 80 mL/min), increasing to 40 mg based on tolerability; avoid use in severe renal impairment. Start at 20 mg once daily for mild or moderate hepatic impairment (Child Pugh Class A or B); avoid in severe hepatic impairment. For patients on ritonavir >=1 week, start at 20 mg once daily and increase to 40 mg based on tolerability.
Pulmonary arterial hypertension Adults and patients >12 years and >40 kg: 62.5 mg orally twice daily for 4 weeks, then 125 mg twice daily; patients >12 years and <=40 kg: 62.5 mg twice daily; pediatric patients <=12 years: weight-based dosing ranging from 16 mg to 64 mg twice daily.
Contraindications
- Concomitant use of any form of organic nitrate, regularly or intermittently
- Concomitant use of guanylate cyclase (GC) stimulators such as riociguat
- Known serious hypersensitivity to tadalafil (ADCIRCA or CIALIS), including Stevens-Johnson syndrome and exfoliative dermatitis
- Pregnancy
- Concomitant use with cyclosporine A
- Concomitant use with glyburide
- Hypersensitivity to bosentan or any component of the product
Adverse Reactions
Most common (>=9%) Headache, myalgia, nasopharyngitis, flushing, respiratory tract infection (upper and lower), pain in extremity, nausea, back pain, dyspepsia, nasal congestion
Serious Hypotension, visual loss, hearing loss, priapism
Postmarketing Serious cardiovascular events (myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, tachycardia), hypersensitivity reactions (urticaria, Stevens-Johnson syndrome, exfoliative dermatitis), migraine, seizure, transient global amnesia, visual field defect, retinal vein occlusion, retinal artery occlusion, NAION, sudden decrease or loss of hearing, priapism
Most common (>=3%) Respiratory tract infection, headache, edema, chest pain, syncope, flushing, hypotension, sinusitis, arthralgia, abnormal serum aminotransferases, palpitations, anemia
Serious Hepatotoxicity, embryo-fetal toxicity, fluid retention, decreased sperm counts, decreases in hemoglobin and hematocrit
Postmarketing Angioedema, unexplained hepatic cirrhosis, liver failure, hypersensitivity/DRESS/anaphylaxis, thrombocytopenia, rash, jaundice, anemia requiring transfusion, neutropenia, leukopenia, nasal congestion, autoimmune hepatitis
Pharmacology
Tadalafil is a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for degradation of cyclic guanosine monophosphate (cGMP) in pulmonary vascular smooth muscle; by inhibiting PDE5, tadalafil increases cGMP concentrations, resulting in relaxation of pulmonary vascular smooth muscle cells and vasodilation of the pulmonary vascular bed.
Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB, blocking the vasoconstrictive and proliferative effects of endothelin-1, a neurohormone elevated in plasma and lung tissue of patients with PAH.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Adcirca
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (4/12) · Qty limit (11/12)
Tracleer
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Adcirca
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Tracleer
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Adcirca
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Tracleer
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Adcirca Co-pay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/fillfill
Janssen CarePath Oral PAH Savings Program: TracleerCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdcircaView full Adcirca profile
TracleerView full Tracleer profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.